Scancell Holdings (FRA:SCP) LT-Debt-to-Total-Asset : 0.88 (As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Scancell Holdings's long-term debt to total assests ratio for the quarter that ended in Oct. 2023 was 0.88.

Scancell Holdings's long-term debt to total assets ratio increased from Oct. 2022 (0.24) to Oct. 2023 (0.88). It may suggest that Scancell Holdings is progressively becoming more dependent on debt to grow their business.

Scancell Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Scancell Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings LT-Debt-to-Total-Asset Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.31

0.49

0.64

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.17	0.49	0.24	0.64	0.88

Scancell Holdings LT-Debt-to-Total-Asset Calculation

Scancell Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2023 is calculated as

LT Debt to Total Assets (A: Apr. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2023 )	/	Total Assets (A: Apr. 2023 )
	=	21.837	/	34.379
	=	0.64

Scancell Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2023 is calculated as

LT Debt to Total Assets (Q: Oct. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Oct. 2023 )	/	Total Assets (Q: Oct. 2023 )
	=	22.503	/	25.667
	=

Scancell Holdings (FRA:SCP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Scancell Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines